TSHA Taysha Gene Therapies, Inc.

NASDAQ
$4.67

Taysha Gene Therapies, Inc. (TSHA) is expected to report earnings on November 11, 2026, after the market close. The consensus earnings estimate is a loss of $0.14 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -23.8% since its last earnings release on August 11, 2026.

Taysha Gene Therapies Missed Consensus Estimates
Tuesday, August 11, 2026 · 4:00 PM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 11
Wednesday · 4:00 PM ET
Earnings Whisper
-
vs ($0.14)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $5.53

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Taysha Gene Therapies, Inc.

Taysha Gene Therapies is on a mission to eradicate monogenic CNS disease.

Sector

Healthcare

Industry

Biotechnology

Held By 4 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.